The virus mutated slowly, and its transmission routes were limited.
En un mismo día, el 23 de julio de 2022, la Organización Mundial de la Salud elevó el brote de viruela del mono a emergencia sanitaria global, y Perú contabilizaba ya 157 casos confirmados en ocho regiones. Lo que este momento revela no es solo la presencia de un nuevo virus, sino la capacidad —y los límites— de los sistemas de salud para anticiparse al caos. Perú llegó a esta encrucijada con cierta preparación, pero también con la conciencia de que la vigilancia, una vez más, es el precio de la calma.
- La OMS declaró emergencia sanitaria internacional el mismo día en que Perú superaba los 150 casos, convirtiendo una alerta local en una urgencia de escala global.
- Lima concentra el 87% de los contagios nacionales, revelando una geografía del riesgo que sigue los patrones de densidad urbana y movilidad internacional.
- El sistema de salud peruano activó protocolos de aislamiento, diagnóstico molecular en 24 horas y cinco hospitales designados antes de que la curva pudiera escapar al control.
- Los especialistas advierten que las personas inmunocomprometidas enfrentan riesgo real de complicaciones graves, aunque la mortalidad global no supera el cuatro por ciento.
- Con 24 pacientes ya dados de alta y ninguna muerte en el país, el brote está contenido por ahora, pero su trayectoria depende de si el virus respeta —o desborda— los sistemas desplegados contra él.
El sábado 23 de julio, la OMS declaró la viruela del mono emergencia sanitaria de importancia internacional. Ese mismo día, Perú registraba 157 casos confirmados distribuidos en ocho regiones, convirtiéndose en uno de los más de setenta países que enfrentaban un brote que ya había infectado a casi catorce mil personas en el mundo.
El Ministerio de Salud peruano no había esperado a que llegara el primer caso para actuar. Desde el 27 de mayo, semanas antes de que se confirmara el contagio inicial, emitió una alerta epidemiológica a establecimientos públicos y privados, ordenando identificar, reportar e investigar casos sospechosos. Se reforzó la vigilancia en aeropuertos, puertos y fronteras terrestres, y se prepararon protocolos de toma de muestras y confirmación de laboratorio.
El primer caso llegó el 26 de junio: un ciudadano extranjero residente en Lima, atendido inicialmente en el Hospital Santa Rosa y luego trasladado a su domicilio al estabilizarse su condición. A partir de ahí, el brote se extendió con una geografía propia: 136 de los 157 casos correspondían a Lima Metropolitana, seguida por Callao, La Libertad y otras regiones con cifras menores.
Lo que hacía la situación manejable era, en parte, la naturaleza del propio virus. El especialista en enfermedades infecciosas Luis Pampa explicó que la mortalidad global no superaba el cuatro por ciento, que la mayoría de los casos eran leves o moderados, y que el virus mutaba lentamente con vías de transmisión más limitadas que el COVID-19. Sin embargo, advirtió que las personas con sistemas inmunes comprometidos corrían riesgo de complicaciones serias.
Perú contaba con cinco hospitales designados en Lima y Callao con áreas de aislamiento, y con capacidad diagnóstica molecular que permitía distinguir la viruela del mono de otras enfermedades similares en menos de veinticuatro horas. Con 24 pacientes ya dados de alta y ninguna muerte registrada en el país, el sistema resistía. Lo que vendría después dependería de si el virus continuaba su expansión medida o aceleraba más allá de lo que los mecanismos desplegados podían contener.
On Saturday, July 23rd, the World Health Organization declared monkeypox a global public health emergency. By that same day, Peru had recorded 157 confirmed cases of the virus across eight regions of the country, making it one of more than seventy nations now grappling with an outbreak that had infected nearly fourteen thousand people worldwide.
The Peruvian health ministry had moved quickly. On May 27th, weeks before the first case appeared domestically, the ministry issued an epidemiological alert to public and private health facilities across the country, instructing them to identify, report, and investigate any suspected cases. The alert came with concrete measures: establishing prevention strategies in communities, intensifying surveillance at airports, ports, and land border crossings, and preparing protocols for sample collection and laboratory confirmation. It was the kind of preparation that, in hindsight, would prove its worth.
The first confirmed case arrived on June 26th. Health Minister Jorge López Peña announced that a foreign national living in Lima had tested positive for monkeypox after undergoing laboratory examination. The patient was isolated, as were family members who had been in contact with him. He was initially treated at Hospital Santa Rosa, then moved to his home once his condition stabilized. The machinery of response had begun to turn.
By late July, the outbreak had spread across the country in a pattern that told its own story. Lima Metropolitana accounted for the vast majority—136 of the 157 cases. Callao had seven. La Libertad had five. Smaller numbers appeared in Ica, Cusco, Loreto, Piura, and Tacna. Twenty-four patients had already been discharged from medical care. All confirmed cases were receiving medical attention and being monitored while health officials worked to identify and track their contacts.
What made the situation manageable, at least for now, was the nature of the virus itself. Luis Pampa, an infectious disease specialist at Peru's National Institute of Health, explained to local media that mortality rates in countries with far larger case numbers did not exceed four percent, and most infections were mild to moderate in severity. The virus mutated slowly, he noted, and its transmission routes were limited compared to other pathogens. This suggested it would not spread with the velocity of COVID-19. Still, Pampa warned that people with compromised immune systems faced risk of serious complications, and he urged the public to remain vigilant and seek medical care at the first sign of symptoms.
Globally, the picture was more sobering. The WHO reported nearly fourteen thousand cases across more than seventy countries. Five deaths had been recorded, all in Africa, where monkeypox was endemic. The virus had arrived in Europe, the Americas, and Latin America, and case numbers continued to climb. Yet Peru's health system had advantages. The country had established five designated hospitals in Lima and Callao equipped with isolation wards: Cayetano Heredia, Dos de Mayo, Villa El Salvador, Ate Vitarte, and Daniel Alcides Carrión. Diagnostic testing, once requiring samples to be sent abroad, could now be completed within twenty-four hours using molecular methods that distinguished monkeypox from similar conditions like chickenpox or hand-foot-and-mouth disease.
The virus itself followed a predictable pattern. After an incubation period of six to sixteen days, infected people entered an invasion phase lasting five days, marked by fever, severe headache, swollen lymph nodes, back pain, and muscle aches. Then came the rash phase, beginning one to three days after fever onset, typically starting on the face and spreading outward. The skin lesions were deep, well-defined, and often umbilicated—dimpled at the center. Transmission occurred through direct contact with these lesions, contaminated objects, or respiratory droplets from coughing, sneezing, or speaking. The path of infection was clear; so was the path to prevention.
As Peru moved forward into late July, the machinery of public health response was in place. Hospitals were ready. Laboratories could deliver results in hours. The public had phone numbers to call, WhatsApp lines to message, email addresses to contact. The outbreak was real, but it was also, for the moment, contained and monitored. What came next would depend on whether the virus continued its measured spread or accelerated beyond the capacity of the systems now arrayed against it.
Notable Quotes
Mortality rates in countries with far larger case numbers do not exceed four percent, and most infections are mild to moderate in severity.— Luis Pampa, infectious disease specialist at Peru's National Institute of Health
The virus mutates slowly and its transmission routes are more limited than other pathogens, suggesting it will not spread with the velocity of COVID-19.— Luis Pampa, National Institute of Health
The Hearth Conversation Another angle on the story
When the WHO made that declaration on July 23rd, did people in Peru understand what it meant for them?
The declaration was a signal that this was no longer a distant problem. Peru had already seen the virus arrive in June, so by late July, people knew it was here. But the declaration gave the outbreak official weight—it meant resources would flow, international attention would focus, and the world would be watching how countries responded.
Why did the health ministry issue that alert back in May, before any cases appeared?
They were reading the global situation. Monkeypox was spreading in Europe and other parts of the world. Peru is a major international hub, with airports and ports connecting it to the rest of the world. The ministry understood that the virus would likely arrive, and they wanted their health system ready to recognize it and act fast when it did.
The numbers seem concentrated in Lima. Does that tell us something?
It tells us where the virus entered and where it found the most connections to spread. Lima is the capital, the most densely populated region, the center of international travel. That's where the first case appeared, and that's where most transmission happened. The smaller numbers in other regions suggest the outbreak hadn't yet taken hold in the same way.
What about the deaths? There were none in Peru, but five globally. Why the difference?
The five deaths were all in Africa, where monkeypox is endemic and where healthcare systems face different constraints. In Peru, cases were being detected early, patients were being isolated and treated, and most infections were mild or moderate. The virus is the same, but the response and the population's immune exposure are different.
The specialist said it wouldn't spread like COVID-19. Did people believe that?
It was a measured reassurance based on biology. Monkeypox mutates slowly and spreads through direct contact or respiratory droplets, not as efficiently as a respiratory virus like COVID. But it was also a warning—the virus was still spreading, still dangerous to certain populations, still worth taking seriously. Reassurance and vigilance had to coexist.
What was the real test at that moment?
Whether Peru's health system could keep pace with the outbreak. They had the protocols, the hospitals, the labs. But outbreaks don't follow plans. The real test was whether they could identify cases fast enough, isolate them, trace contacts, and prevent the virus from finding new networks to spread through. That was the work ahead.